Meeting
2023 ASCO Annual Meeting
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.
Authors
Nabeel Badri
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Nabeel Badri , Jason Zittel , Andrea M. Baran , Efrat Dotan , Joleen M. Hubbard , Marcus Smith Noel , Aram F Hezel , Mohamedtaki Abdulaziz Tejani , Supriya Gupta Mohile
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Geriatric Models of Care
Clinical Trial Registration Number
NCT02466009
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12047)
DOI
10.1200/JCO.2023.41.16_suppl.12047
Abstract #
12047
Poster Bd #
415
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population.
First Author: Katherine Clifton
Poster
2016 ASCO Annual Meeting
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
First Author: Yasutoshi Kuboki
Poster
2014 Gastrointestinal Cancers Symposium
MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer.
First Author: Diogo Bugano Diniz Gomes
Poster
2012 ASCO Annual Meeting
The influence of age plus standard clinical approach with or without comprehensive geriatric assessment (CGA) on treatment decisions in older cancer patients: Final results.
First Author: Lore Decoster